Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on March 28, 2019. The report discloses the departure of Dr. Mark A. Tepper, the Company's President and Chief Scientific Officer, and his subsequent engagement as an external consultant.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the compensation arrangement for the departing executive:
- Consulting Fee: $33,667.00 per month for an 18-month term.
- COBRA Premiums: Company to pay for 18 months from the separation date.
- Stock Option Vesting: Continued vesting of outstanding options during the consulting term.
Material Changes
The primary material change is the transition of Dr. Mark A. Tepper from an executive officer to a consultant effective April 1, 2019. His last day of employment was March 31, 2019. This change supersedes severance benefits that would have otherwise been payable under his prior employment agreement.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance or outlook. Management commentary is limited to the terms of the separation and consulting agreements:
- Consulting Scope: Dr. Tepper will provide advisory services on the pre-clinical and clinical development of the Company's endocannabinoid platform and business development efforts.
- Restrictions: Dr. Tepper agreed to a 90-day lock-up on share sales and a limit of 250,000 shares sold per calendar quarter during the consulting term.
- Covenants: The agreements include customary confidentiality, non-disparagement, non-competition, and non-solicitation provisions.
Important Facts for Investor Verification
- Verify the total cash outflow for the 18-month consulting term ($606,006) and associated COBRA costs.
- Confirm the impact of Dr. Tepper's departure on the Company's endocannabinoid platform development timeline.
- Review the attached Exhibits 10.1 and 10.2 for the full legal text of the Separation and Consulting Agreements.
- Monitor the Company's stock trading volume for potential sales by Dr. Tepper after the 90-day lock-up expires.